Trials / Completed
CompletedNCT00652223
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYT005-AllQbG10 | Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT |
Timeline
- Start date
- 2005-03-01
- Completion
- 2005-11-01
- First posted
- 2008-04-03
- Last updated
- 2008-04-09
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00652223. Inclusion in this directory is not an endorsement.